Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/1669827 since 2019-02-05T11:41:52Z

Published version:
DOI:10.1136/annrheumdis-2018-213496

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
This is the author's final version of the contribution published as:
Sciascia S, Rubini E, Radin M, Cecchi I, Rossi D, Roccatello D.

The publisher's version is available at:
https://ard.bmj.com/content/77/11/1694.long

When citing, please refer to the published version.

Link to this full text:
http://hdl.handle.net/2318/1669827

This full text was downloaded from iris-Aperto: https://iris.unito.it/
Anticardiolipin and anti-Beta 2 glycoprotein-I antibodies disappearance in patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome while on belimumab

Sciascia S*, Rubini E*, Radin M, Cecchi I, Rossi D, Roccatello D.

Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy.

*equally contributed

Running Title: aPLnegativization in SLE and APS patients treated with belimumab

Key words:

Corresponding Author:

Savino Sciascia, MD, PhD;

Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital

Piazza del Donatore di Sangue 3, 10154, Turin, Italy.

Email savino.sciascia@unito.it Tel +390112402056 Fax +390112402052

This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation
Sir,

The current management of Antiphospholipid Syndrome (APS) centres on attenuating the pro-coagulant state while balancing the haemorrhagic risks[1]. This approach relies mainly on a thrombo-prophylaxis strategy rather than targeting pathogenic antiphospholipid antibodies (aPL)-mediated pathways.

Herewith, we report the aPL disappearance in three patients with APS associated to Systemic Lupus Erythematosus (SLE) while on treatment with belimumab, potentially paving the way for development of new targeted therapies for APS. Belimumab is a monoclonal antibody that works by blocking the B-lymphocyte stimulator and avoiding B-cell activation[2]. It is the first biological drug approved for the treatment of autoantibody positive SLE in active phase, and it has shown its capability to reduce the antibodies levels, including anti-double stranded-DNA[3]. Intriguingly, in murine models of APS in the setting of SLE, Belimumab proved its ability to stop disease progression and to reduce mortality rate [4]. However, its use in APS patients needs further investigation.

After chart-reviewing all the aPL-positive SLE patients treated in our centre with belimumab, investigating the changes in the aPL profile, we identified three patients with diagnosis of SLE[5] and APS (fulfilling Sydney classification criteria)[6] and persistent aPL positivity (confirmed in more than 6 occasions over the previous 5 years before starting Belimumab) in whom we observed aPL disappearance. Clinical characteristics are detailed in Table 1 and aPL testing methodology is detailed in Supplementary Material S1. All patients received belimumab for active SLE (i.v. 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter). After 8 months since belimumab was started, Patient#1 became persistently negative for anti-β2-glycoprotein I antibodies (anti-β2GPI), while anti-cardiolipin
antibodies (aCL) titre significantly decreased. While on treatment, anti-β2GPI and aCL levels both turned negative in Patient#2. Interestingly, after being on belimumab for one year, she planned a pregnancy and preferred to suspend the treatment, after 8 months since suspension, antiβ2GPI antibodies were detectable again. Patient#3 was persistently negative for aCL while being on belimumab (28 months). When he discontinued the therapy for lack of response, aCL antibodies returned positive after 2 months. Figure 1 illustrates aPL titres of the three patients in relationship with belimumab therapy. Two patients (#1 and #3) persistently tested positive for LA despite Belimumab treatment. No patients experienced hypogammaglobulinemia while on belimumab and IgG/IgM levels were constantly within normal range. Of note, none of the patients was started on a concomitant immunosuppressive treatment when Belimumab was begun. However, a synergic role of hydroxychloroquine in the aCL and anti-beta2GPI disappearance cannot be excluded.

Persistent aPL disappearance is a hot topic of discussion in the field of APS, but the clinical significance of sero-negativization is still to be elucidated[7,8]. At the best of our knowledge, despite its limitations (e.g. sample size and retrospective design), this pilot study is the first report of aPL negativization after starting therapy with belimumab. Even more interesting, after stopping the treatment (mean time of two months) patients turned to be positive tested for IgG aPL again. The clinical relevance of these findings should be investigated in prospective multicenter studies, but if confirmed, they might modify the therapeutic management of APS patients. Potentially, the current ‘anti-thrombotic’ approach to APS patients will be at least combined in the future with an ‘immunomodulatory’ approach.
References


Legend of tables and Figures

Table 1. Characteristics of the patients included in the study

Figure 1. aPL titers of the three patients in relationship with belimumab therapy
Table 1. Characteristics of the patients included in the study

<table>
<thead>
<tr>
<th>Patient #1</th>
<th>Sex</th>
<th>Age</th>
<th>Diagnosis</th>
<th>Associated Autoimmune Disease</th>
<th>aPL positivity</th>
<th>APS Clinical Events</th>
<th>Indication for starting belimumab</th>
<th>Concomitant immunomodulant treatment</th>
<th>Previous Immunomodulant treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>M</strong> 51</td>
<td>APS</td>
<td>SLE</td>
<td>LA, aCLlgG, anti-β2GPI lgG</td>
<td>Sub-popliteal arterialthrombosis</td>
<td>Cutaneous*(face, upper trunk, arms) and articular involvement**</td>
<td>Low doses of steroids (5 mg/dl) and HCQ</td>
<td>IVIG, high doses of steroids</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Patient #2 | F   | 33  | APS       | aCL IgG, anti-β2GPI IgM | 3 miscarriages <10^5 week of gestation | Haematological *** and articular involvement** | Low doses of steroids (5 mg/dl) and HCQ | MMP, high doses of steroids, IVIG, AZA |

| Patient #3 | M   | 39  | APS       | LA, aCLlgG | 3 episodes of DVT, severe thrombocytopenia | Haematological **** involvement | Low doses of steroids (5 mg/dl) | High doses of steroids, RTX and CYC |

APS – Antiphospholipid Syndrome; SLE – Systemic Lupus Erythematosus; aPL – antiphospholipid antibodies; LA- Lupus Anticoagulant; aCL- anticardiolipin antibodies; β2GPI- anti-β2Glycoprotein I antibodies; DVT – Deep Vein Thrombosis; HCQ – hydroxychloroquine;IVIG, intravenous immunoglobulin; AZA, azathioprine; Rituximab, RTX; MMP, Mycophenolate; CYC, Cyclophosphamide, CYC.

*Defined as Annular scaly plaques, hypopigmentation; scaly erythematous patches, reticulate erythema

**Defined as inflammatory arthritis involving more than 3 joints

***Defined as thrombocytopenia (<100.000 platelets X10^9/L), leucopenia(<2.500 white blood cells X10^9/L) and anemia (Hemoglobin <9g/dL)

**** Defined as thrombocytopenia (<50.000 platelets X10^9/L), and leucopenia(<3.000 white blood cells X10^9/L)
Acknowledgments: None

Disclosure of Conflicts of Interest: None declared

Funding: None declared
Authors Contribution

ER and SS designed the study, performed data analysis and drafted the manuscript. ER, IC, DR1, MR, DR2, and SS gave a substantial contribution to concept and study design and participated in the interpretation of data. All the Authors gave the final approval of the version to be published.